Skip to main content

PTSD

9
Pipeline Programs
25
Companies
40
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
5
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

24 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
Paroxetine CRPhase 4
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
4 programs
1
Apollo Wearable SystemPhase 21 trial
Experiential Avoidance in Combat Veterans With and Without Posttraumatic Stress DisorderN/A1 trial
Project Safe Guard - TraumaN/A1 trial
Rapid Resolution TherapyN/A1 trial
Active Trials
NCT01652430Completed78Est. Jul 2013
NCT06876740Recruiting168Est. Sep 2028
NCT04073004Completed30Est. Jun 2023
+1 more trials
Humanetics Corp.
Humanetics Corp.MN - Roseville
1 program
1
7-Keto DehydroepiandrosteronePhase 21 trial
Active Trials
NCT01861847Completed71Est. Dec 2014
Apollo Therapeutics
Apollo TherapeuticsUK - Cambridge
1 program
1
Apollo Wearable SystemPhase 2
Marinus Pharmaceuticals
1 program
1
GanaxolonePhase 21 trial
Active Trials
NCT01339689Completed112Est. Mar 2014
Azevan Pharmaceuticals
1 program
1
SRX246Phase 25 trials
Active Trials
NCT07328529Not Yet Recruiting80Est. Mar 2028
NCT02922166Unknown36Est. Dec 2019
NCT02733614Terminated33Est. Mar 2021
+2 more trials
Sage Therapeutics
Sage TherapeuticsMA - Cambridge
1 program
1
BrexanolonePhase 11 trial
Active Trials
NCT05223829Active Not Recruiting25Est. Dec 2025
ReST Therapeutics
ReST TherapeuticsCT - New Haven
1 program
1
FluoroethylnormemantinePhase 11 trial
Active Trials
NCT05921929Withdrawn0Est. May 2024
Lundbeck
LundbeckDenmark - Copenhagen
1 program
1
Lu AG06466Phase 11 trial
Active Trials
NCT04597450Completed35Est. Feb 2023
Tonix Pharmaceuticals
Tonix PharmaceuticalsBERKELEY HEIGHTS, NJ
7 programs
TNX-102 SLPHASE_21 trial
TNX-102 SLPHASE_21 trial
TNX-102 SLPHASE_21 trial
TNX-102 SLPHASE_31 trial
TNX-102 SLPHASE_31 trial
+2 more programs
Active Trials
NCT02421679Completed159Est. May 2016
NCT02277704Completed245Est. May 2016
NCT05372887Withdrawn0Est. Nov 2022
+4 more trials
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
2 programs
BREATHE InterventionN/A1 trial
Structured Approach TherapyN/A1 trial
Active Trials
NCT04385498Completed14Est. Oct 2023
NCT01627548Withdrawn0Est. Nov 2013
Sound Pharmaceuticals
2 programs
I MOVE!+UPN/A1 trial
RETevalN/A1 trial
Active Trials
NCT05755100Completed9Est. Oct 2024
NCT06363968Recruiting50Est. Sep 2030
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
PE-PCN/A1 trial
Written Exposure TherapyN/A1 trial
Active Trials
NCT03711266Completed35Est. Sep 2020
NCT05486793Recruiting240Est. Jul 2027
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Big MindN/A1 trial
Active Trials
NCT02541630WithdrawnEst. Apr 2016
Bryan Corporation
Bryan CorporationOH - Cincinnati
1 program
BiofeedbackN/A1 trial
Active Trials
NCT00625105Unknown30Est. Dec 2014
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Clinical Observation and Risk Factor Analysis of the Incidence of Postoperative PTSD in ChildrenN/A1 trial
Active Trials
NCT07088692Not Yet Recruiting400Est. May 2026
Combined Therapeutics
1 program
Eye Movement Desensitization and Reprocessing TherapyN/A1 trial
Active Trials
NCT06955845Active Not Recruiting60Est. Dec 2025
Carrick Therapeutics
Carrick TherapeuticsIreland - Dublin
1 program
Functional Neurological RehabilitationN/A1 trial
Active Trials
NCT02003352Completed98Est. Sep 2014
Neurovalens
NeurovalensUK - Belfast
1 program
Modius SleepN/A1 trial
Active Trials
NCT04780893Withdrawn0Est. Apr 2022
Providence Therapeutics
1 program
NEST-1N/A1 trial
Active Trials
NCT02981381Completed23Est. Oct 2018
Alliance Pharmaceuticals
1 program
PARTS-SUDN/A1 trial
Active Trials
NCT06207409Completed19Est. Mar 2025
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Traditional Exposure TherapyN/A1 trial
Active Trials
NCT06740487Recruiting40Est. Dec 2027
Acacia Pharma
Acacia PharmaUK - Cambridge
1 program
non-invasive vagus nerve stimulationN/A1 trial
Active Trials
NCT07523685Recruiting40Est. Mar 2027
GSK
GSKLONDON, United Kingdom
1 program
Paroxetine CRPHASE_41 trial
Active Trials
NCT00330239Completed25Est. May 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
GSKParoxetine CR
Tonix PharmaceuticalsTNX-102 SL
Tonix PharmaceuticalsTNX-102 SL 5.6 mg
Tonix PharmaceuticalsTNX-102 SL
Tonix PharmaceuticalsTNX-102 SL
Azevan PharmaceuticalsSRX246
Tonix PharmaceuticalsTNX-102 SL
Colorado TherapeuticsApollo Wearable System
Azevan PharmaceuticalsSRX246
Azevan PharmaceuticalsSRX246
Tonix PharmaceuticalsTNX-102 SL
Tonix PharmaceuticalsTNX-102 SL
Humanetics Corp.7-Keto Dehydroepiandrosterone
Marinus PharmaceuticalsGanaxolone
Azevan PharmaceuticalsSRX246

Showing 15 of 40 trials with date data

Clinical Trials (40)

Total enrollment: 3,327 patients across 40 trials

NCT00330239GSKParoxetine CR

Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence

Start: Jan 2003Est. completion: May 200525 patients
Phase 4Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

Start: Mar 2019Est. completion: Apr 2020192 patients
Phase 3Terminated

A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD

Start: Apr 2018Est. completion: Sep 201993 patients
Phase 3Completed

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

Start: Jun 2017Est. completion: Jul 2018190 patients
Phase 3Terminated

Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD

Start: Mar 2017Est. completion: Jul 2018358 patients
Phase 3Terminated

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

Start: Mar 2026Est. completion: Mar 202880 patients
Phase 2Not Yet Recruiting

Safety and Efficacy Study of TNX-102 SL in Participants With PTSD

Start: Oct 2022Est. completion: Nov 20220
Phase 2Withdrawn
NCT05019651Colorado TherapeuticsApollo Wearable System

Acceptability and Feasibility of Apollo in Veterans With a History of PTSD

Start: Feb 2022Est. completion: Jun 202363 patients
Phase 2Completed

Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD

Start: Dec 2016Est. completion: Mar 202133 patients
Phase 2Terminated

Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

Start: May 2016Est. completion: Dec 2018106 patients
Phase 2Completed

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

Start: Apr 2015Est. completion: May 2016159 patients
Phase 2Completed

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

Start: Oct 2014Est. completion: May 2016245 patients
Phase 2Completed
NCT01861847Humanetics Corp.7-Keto Dehydroepiandrosterone

7-Keto DHEA for the Treatment of PTSD

Start: Feb 2013Est. completion: Dec 201471 patients
Phase 2Completed

Ganaxolone in Posttraumatic Stress Disorder (PTSD)

Start: Apr 2011Est. completion: Mar 2014112 patients
Phase 2Completed

Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder

Start: May 2014Est. completion: May 201697 patients
Phase 1/2Completed
NCT05921929ReST TherapeuticsFluoroethylnormemantine

First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)

Start: May 2024Est. completion: May 20240
Phase 1Withdrawn

Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

Start: Aug 2023Est. completion: Dec 202525 patients
Phase 1Active Not Recruiting

Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)

Start: Sep 2020Est. completion: Feb 202335 patients
Phase 1Completed

Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

Start: Feb 2017Est. completion: Dec 201936 patients
Phase 1Unknown

Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers

Start: Mar 2010Est. completion: Jul 201024 patients
Phase 1Completed

Study of SRX246 Capsules in Healthy Adult Volunteers

Start: May 2009Est. completion: Sep 200949 patients
Phase 1Completed
NCT07523685Acacia Pharmanon-invasive vagus nerve stimulation

Non-invasive Vagus Nerve Stimulation (nVNS) for Post-Traumatic Stress Disorder (PTSD)

Start: Mar 2026Est. completion: Mar 202740 patients
N/ARecruiting
NCT06740487Johnson & JohnsonTraditional Exposure Therapy

Advanced Wireless Augmented Reality-Enhanced Exposure Therapy for Posttraumatic Stress Disorder

Start: Sep 2025Est. completion: Dec 202740 patients
N/ARecruiting
NCT07088692UNION therapeuticsClinical Observation and Risk Factor Analysis of the Incidence of Postoperative PTSD in Children

Clinical Observation and Risk Factor Analysis of the Incidence of Postoperative PTSD in Children

Start: Aug 2025Est. completion: May 2026400 patients
N/ANot Yet Recruiting
NCT06876740Colorado TherapeuticsProject Safe Guard - Trauma

Project Safe Guard-Trauma

Start: May 2025Est. completion: Sep 2028168 patients
N/ARecruiting
NCT06955845Combined TherapeuticsEye Movement Desensitization and Reprocessing Therapy

Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) Therapy Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in the Treatment of Post-Traumatic Stress Disorder

Start: May 2025Est. completion: Dec 202560 patients
N/AActive Not Recruiting

Biomarkers in the Retina for Prognosticating Mental Health Treatments

Start: Feb 2024Est. completion: Sep 203050 patients
N/ARecruiting

Program for Alleviating and Reducing Trauma, Stress, and Substance Use

Start: Sep 2023Est. completion: Mar 202519 patients
N/ACompleted

Primary Care Intervention for PTSD in Ethiopia

Start: Jun 2023Est. completion: Oct 202314 patients
N/ACompleted
NCT05486793Human BioSciencesWritten Exposure Therapy

Treatment for Antepartum Posttraumatic Stress Disorder/PTSD Study

Start: Mar 2023Est. completion: Jul 2027240 patients
N/ARecruiting

I MOVE!+UP: Piloting an Integrated Weight Management Program for Veterans With PTSD

Start: Jan 2023Est. completion: Oct 20249 patients
N/ACompleted

Electrical Vestibular Nerve Stimulation (VeNS) as a Method of Sleep Management in People With PTSD

Start: Feb 2022Est. completion: Apr 20220
N/AWithdrawn
NCT04073004Colorado TherapeuticsRapid Resolution Therapy

RRT for PTSD Symptoms in Survivors of Sexual Violence

Start: Nov 2020Est. completion: Jun 202330 patients
N/ACompleted

Implementing PTSD Treatment in FQHCs for Michigan Medicaid Enrollees

Start: Nov 2018Est. completion: Sep 202035 patients
N/ACompleted

Synchronized Transcranial Magnetic Stimulation for PTSD

Start: Oct 2016Est. completion: Oct 201823 patients
N/ACompleted

Big Mind for Veterans With PTSD

Start: Aug 2015Est. completion: Apr 2016
N/AWithdrawn
NCT02003352Carrick TherapeuticsFunctional Neurological Rehabilitation

Study of PTSD in Military Veterans Who Have Suffered Traumatic Brain Injuries

Start: Mar 2014Est. completion: Sep 201498 patients
N/ACompleted
NCT01627548Angeles TherapeuticsStructured Approach Therapy

UCLA Couples Counseling for Combat Veterans

Start: Jan 2012Est. completion: Nov 20130
N/AWithdrawn

Using Heart Rate Variability Biofeedback to Improve Attention and Memory in PTSD+ Combat Veterans

Start: Jan 2011Est. completion: Dec 201430 patients
N/AUnknown
NCT01652430Colorado TherapeuticsExperiential Avoidance in Combat Veterans With and Without Posttraumatic Stress Disorder

Experiential Avoidance in Combat Veterans With and Without Posttraumatic Stress Disorder

Start: Oct 2010Est. completion: Jul 201378 patients
N/ACompleted

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 actively recruiting trials targeting 3,327 patients
25 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.